The following posters will be presented:

METIS: A Phase III Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC
Date and Time: Tuesday, September 8 from 9:30 AM – 5:00 PM

Location: Exhibit Hall (Hall B+C)
Poster: P2.01-093
Session: Treatment of Advanced Disease – Trials in Progress

LUNAR: A Phase III Study of Front-Line Chemotherapy with TTFields for Advanced Squamous NSCLC
Date and Time: Tuesday, September 9 from 9:30 AM – 5:00 PM
Location: Exhibit Hall (Hall B+C)
Poster: P3.01-091
Session: Treatment of Advanced Disease – NSCLC

STELLAR: A Phase II Trial of TTFields with Chemotherapy for First Line Treatment of Malignant Mesothelioma
Date and Time: Tuesday, September 8 from 9:30 AM – 5:00
PM Location: Exhibit Hall (Hall B+C)
Poster: P2.08-013
Session: Thymoma, Mesothelioma and Other Thoracic Malignancies - Mesothelioma

About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) therapy is delivered by a portable, non-invasive medical device designed for continuous use by patients. In vitro and in vivo studies have shown that TTFields therapy slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.

TTFields therapy is not approved for the treatment of brain metastases and malignant mesothelioma. In the United States and Japan, TTFields therapy is not approved for the treatment of NSCLC. The safety and effectiveness of TTFields therapy in these indications has not been established.

Approved Indications
The US FDA has approved the TTFields therapy delivery system, Optune (previously known as the NovoTTF-100A System), for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed GBM, following histologically or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Patients should only use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301.

In the European Union, Optune is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after surgery and radiation therapy with adjuvant temozolomide. Treatment may be given together with maintenance temozolomide and after maintenance temozolomide is stopped.

More HCB News